---
schema_version: "secwatch.filing_event.v1"
accession: "0000927066-22-000131"
form_type: "8-K"
ticker: "DVA"
cik: "0000927066"
company_name: "DAVITA INC."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:45:27.864296+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DaVita Q2 2022 EPS $2.30, revenue $2.93B; six-month net income down 27% YoY

## Summary
- Q2 2022 revenue $2.927B, operating income $433M, diluted EPS $2.30 (vs Q1 2022 EPS $1.61).
- Six-month net income $387M ($3.90/sh) vs $531M ($4.72/sh) in prior year, down 27%.
- U.S. normalized non-acquired treatment growth was -1.9% YoY; per-day treatments up 0.9% QoQ.
- Patient care costs per treatment improved to $247.14 (Q2) from $252.61 (Q1); G&A rose to $241M.
- Repurchased 3.9M shares at $95.56 in Q2; additional 0.9M at $82.94 in July.

## SEC filing metadata
- accession: 0000927066-22-000131
- form_type: 8-K
- ticker: DVA
- cik: 0000927066
- company_name: DAVITA INC.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/927066/000092706622000131/0000927066-22-000131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/927066/000092706622000131/dva-20220801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000927066-22-000131
- JSON: https://secwatch.observer/filing/0000927066-22-000131.json
- Plain text: https://secwatch.observer/filing/0000927066-22-000131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.